Stifel Nicolaus reiterated their buy rating on shares of Clovis Oncology Inc. (NASDAQ:CLVS) in a research report released on Monday. They currently have a $45.00 price target on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on CLVS. Piper Jaffray Cos. reissued a hold rating and set a $14.00 price objective on shares of Clovis Oncology in a research note on Wednesday, June 29th. Credit Suisse Group AG reaffirmed a hold rating on shares of Clovis Oncology in a research note on Tuesday, July 12th. SunTrust Banks Inc. assumed coverage on Clovis Oncology in a research note on Friday, August 5th. They issued a buy rating and a $25.00 price target for the company. JPMorgan Chase & Co. reaffirmed a hold rating and issued a $13.00 price target on shares of Clovis Oncology in a research note on Tuesday, August 9th. Finally, Zacks Investment Research raised Clovis Oncology from a hold rating to a buy rating and set a $18.00 price target for the company in a research note on Thursday, August 11th. Seven investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $36.39.

Clovis Oncology (NASDAQ:CLVS) traded up 2.35% during mid-day trading on Monday, hitting $32.60. 102,323 shares of the stock traded hands. Clovis Oncology has a 1-year low of $11.57 and a 1-year high of $109.18. The company has a 50-day moving average of $31.36 and a 200 day moving average of $19.25. The firm’s market capitalization is $1.26 billion.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.06. During the same period in the previous year, the business posted ($2.10) EPS. On average, equities research analysts anticipate that Clovis Oncology will post ($9.25) EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CLVS. Creative Planning boosted its position in shares of Clovis Oncology by 524.4% in the third quarter. Creative Planning now owns 11,638 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 9,774 shares during the last quarter. Royal Bank of Canada boosted its position in Clovis Oncology by 2,075.9% in the second quarter. Royal Bank of Canada now owns 18,212 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 17,375 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in Clovis Oncology by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 105,186 shares of the biopharmaceutical company’s stock worth $1,444,000 after buying an additional 3,444 shares during the last quarter. Palo Alto Investors LLC boosted its position in Clovis Oncology by 9.9% in the second quarter. Palo Alto Investors LLC now owns 3,804,088 shares of the biopharmaceutical company’s stock worth $52,192,000 after buying an additional 342,723 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in Clovis Oncology by 24.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 24,046 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 4,795 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

About Clovis Oncology

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.